Literature DB >> 8618909

Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes.

L V Tsui1, L G Guidotti, T Ishikawa, F V Chisari.   

Abstract

Using transgenic mice that replicate the hepatitis B virus (HBV) genome, we recently demonstrated that class I-restricted, hepatitis B surface antigen-specific cytotoxic T lymphocytes (CTLs) can noncytolytically eliminate HBV pregenomic and envelope RNA transcripts from the hepatocyte. We now demonstrate that the steady-state content of these viral transcripts is profoundly reduced in the nucleus and cytoplasm of CTL-activated hepatocytes, but their transcription rates are only slightly reduced. Additionally, we demonstrate that transcripts covering the HBV X coding region are resistant to downregulation by the CTL. These results imply the existence of CTL-inducible hepatocellular factors that interact with a discrete element(s) between nucleotides 3157 and 1239 within the viral pregenomic and envelope transcripts and mediate their degradation, thus converting the hepatocyte from a passive victim to an active participant in the host response to HBV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8618909      PMCID: PMC40365          DOI: 10.1073/pnas.92.26.12398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA.

Authors:  P R Bohjanen; B Petryniak; C H June; C B Thompson; T Lindsten
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

2.  The adenosine-uridine binding factor recognizes the AU-rich elements of cytokine, lymphokine, and oncogene mRNAs.

Authors:  P Gillis; J S Malter
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

3.  Immunosuppressive function of hepatitis B antigens in vitro: role of endoribonuclease V as one potential trans inactivator for cytokines in macrophages and human hepatoma cells.

Authors:  C Jochum; R Voth; S Rossol; K H Meyer zum Büschenfelde; G Hess; H Will; H C Schröder; R Steffen; W E Müller
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

Review 4.  Recovery from acute virus infection. Role of cytotoxic T lymphocytes in the elimination of lymphocytic choriomeningitis virus from spleens of mice.

Authors:  F Lehmann-Grube; D Moskophidis; J Löhler
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Identification of an AUUUA-specific messenger RNA binding protein.

Authors:  J S Malter
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

6.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

7.  Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice.

Authors:  T Moriyama; S Guilhot; K Klopchin; B Moss; C A Pinkert; R D Palmiter; R L Brinster; O Kanagawa; F V Chisari
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

8.  Alpha interferon suppresses hepatitis B virus enhancer activity and reduces viral gene transcription.

Authors:  R Tur-Kaspa; L Teicher; O Laub; A Itin; D Dagan; B R Bloom; D A Shafritz
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

9.  Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA.

Authors:  Y Hayashi; K Koike
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

10.  Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.

Authors:  G H Wong; D V Goeddel
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

View more
  43 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

2.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.

Authors:  Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

Review 5.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

6.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.

Authors:  A Lieber; C Y He; L Meuse; D Schowalter; I Kirillova; B Winther; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 7.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

Authors:  Jing You; Lin Zhuang; Hong-Ying Cheng; Shou-Ming Yan; Lan Yu; Jun-Hua Huang; Bao-Zhang Tang; Meng-Ling Huang; Yong-Liang Ma; Virasakdi Chongsuvivatwong; Hutcha Sriplung; Alan Geater; Yan-Wei Qiao; Rong-Xue Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site.

Authors:  T Heise; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

10.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.

Authors:  L G Guidotti; P Borrow; M V Hobbs; B Matzke; I Gresser; M B Oldstone; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.